KM Pharmaceutical, CEO and Company Sequentially Repurchase Treasury Shares... Hits Upper Limit on Shareholder Return Expectations

On July 30, KM Pharmaceutical Co., Ltd. (225430) hit the upper price limit early in the trading session, powered by a series of shareholder-friendly policies such as enhanced responsible management by the CEO and the repurchase of treasury shares. In the market, investment sentiment is seen to have improved significantly as the company's low valuation relative to its asset value has come into focus.

As of 10:30 a.m. on this day, KM Pharmaceutical was trading at 1,755 won, up 30.00% from the previous trading day, reaching the daily price limit increase.

The company's recently announced shareholder return policies are cited as the background for the stock's rally. On July 28, KM Pharmaceutical disclosed its decision to buy back treasury shares worth about 300 million won, equivalent to approximately 3.72% of the total issued shares. The company explained that the purpose of this buyback is to enhance shareholder value and stabilize the share price.

Prior to this, on July 15, CEO Paik Seungwon directly participated in a private placement capital increase by contributing about 1 billion won of his own funds. This demonstrated his commitment to responsible management and the company’s growth through concrete action.

In a shareholder letter on July 16, CEO Paik stated, "Our top management priority will be to resolve the designation as an administrative issue and to restore corporate value," adding, "I will do my utmost to ensure responsible management and the continued enhancement of our corporate value."

The market has responded positively to both the largest shareholder’s direct investment and the company’s treasury share buyback being executed concurrently. This is often interpreted as a strong signal of management's commitment to enhancing corporate value, particularly when management injects personal funds and the company buys back its own shares.

In particular, KM Pharmaceutical is drawing attention for being undervalued relative to its asset value. As of the closing price on July 29, the price-to-book ratio (PBR) stood at about 0.27 times, making it one of the most notable low-PBR stocks, with the market capitalization considerably lower than the value of its assets such as production facilities and real estate. The latest shareholder-friendly measures further highlight this undervaluation, leading to increased demand from value investors.

An industry source in the securities sector commented, "A CEO’s responsible management and treasury share repurchase are generally accepted as signs of a willingness to enhance corporate value. The effect on investor sentiment is often more pronounced in companies with smaller market capitalizations."

KM Pharmaceutical completed payment for its capital increase on July 24 and plans to sequentially acquire treasury shares going forward. Additionally, the company is expanding its exports to Asian markets, including China and Vietnam, centered on its flagship product ‘Pororo Toothpaste,’ and is actively pushing into the North American market based on the competitiveness of its own brand.

This content was produced with the assistance of AI translation services.